(NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug candidate AK006 after it failed to ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 ...

Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives – – Management to host conference call and webcast today at 8:30 am E.T ...

The biotech bet its future on AK006 one year ago after its previous lead candidate lirentelimab chalked up two phase 2 flops to extend its long losing streak. Allakos identified AK006, which ...

Shares of Allakos (ALLK) are down 75% in pre-market trading after the company announced it will discontinue further clinical development of AK006 after the preclinical inhibitory effects observed ...

Allakos Inc. to discontinue AK006 development for CSU after phase 1 trial showed no clinical benefit despite favorable safety results. Restructuring includes a 75% workforce reduction and ...

The San Carlos-based firm had tested its hives drug, called AK006, in a 14-week trial with 34 adult patients. The patients didn’t see serious side effects, but the drug also didn’t outperform ...

AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).